Patents by Inventor Vafa Shahabi

Vafa Shahabi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods comprising KLK3 or FOLH1 antigen
    Patent number: 11446369
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: September 20, 2022
    Assignees: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yvonne Paterson, John Rothman, Vafa Shahabi
  • COMPOSITIONS AND METHODS COMPRISING KLK3 OR FOLH1 ANTIGEN
    Publication number: 20200069785
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Application
    Filed: November 1, 2019
    Publication date: March 5, 2020
    Applicants: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yvonne PATERSON, John ROTHMAN, Vafa SHAHABI
  • Dual delivery system for heterologous antigens
    Patent number: 9650639
    Abstract: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: May 16, 2017
    Assignee: ADVAXIS, INC.
    Inventors: Paulo Maciag, Anu Wallecha, Vafa Shahabi
  • Dual delivery system for heterologous antigens
    Patent number: 9644212
    Abstract: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: May 9, 2017
    Assignee: ADVAXIS, INC.
    Inventors: Paulo Maciag, Anu Wallecha, Vafa Shahabi
  • COMPOSITIONS AND METHODS COMPRISING KLK3 OR FOLH1 ANTIGEN
    Publication number: 20170100469
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 13, 2017
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, ADVAXIS, INC.
    Inventors: Yvonne PATERSON, John ROTHMAN, Vafa SHAHABI
  • Compositions and methods comprising KLK3 or FOLH1 antigen
    Patent number: 9549973
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 24, 2017
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, ADVAXIS, INC.
    Inventors: Yvonne Paterson, John Rothman, Vafa Shahabi
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
    Publication number: 20160361401
    Abstract: This invention provides compositions and methods for treating and vaccinating against a HER2/neu antigen-expressing tumor and inducing an immune response against the same in a subject.
    Type: Application
    Filed: February 25, 2015
    Publication date: December 15, 2016
    Inventors: Vafa Shahabi, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew Seavey
  • COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
    Publication number: 20150366955
    Abstract: This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
    Type: Application
    Filed: February 25, 2014
    Publication date: December 24, 2015
    Inventors: VAFA SHAHABI, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew M. Seavey
  • COMPOSITIONS AND METHODS COMPRISING KLK3 OR FOLH1 ANTIGEN
    Publication number: 20150335721
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 26, 2015
    Inventors: YVONNE PATERSON, JOHN ROTHMAN, VAFA SHAHABI
  • COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
    Publication number: 20150297702
    Abstract: This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a human subject.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 22, 2015
    Inventors: VAFA SHAHABI, ANU WALLECHA, PAULO C. MACIAG, YVONNE PATERSON, MATTHEW SEAVEY, NICOLA MASON
  • BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT
    Publication number: 20150299804
    Abstract: Provided herein are prognostic and diagnostic methods for predicting likelihood of clinical response of a subject having cancer to treatment with an immunotherapeutic agent. Also provided herein are methods for treating a subject having cancer with an immunotherapeutic agent after determining likelihood of clinical response of the subject to such treatment.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 22, 2015
    Inventors: Maksym ARTOMOV, Scott D. Chasalow, Kevin Daniel Fowler, Ruiru Ji, Vafa Shahabi, Fadi George Towfic, Benjamin James Zeskind
  • COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
    Publication number: 20150238584
    Abstract: This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
    Type: Application
    Filed: February 25, 2014
    Publication date: August 27, 2015
    Inventors: VAFA SHAHABI, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew M. Seavey
  • Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
    Patent number: 9084747
    Abstract: This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant and several sub-dominant epitopes of the antigen.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: July 21, 2015
    Assignees: Advaxis, Inc., The Trustees Of The University Of Pennsylvania
    Inventors: Vafa Shahabi, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Matthew Seavey
  • ANTI-TUMOR ANTIBODIES AS PREDICTIVE OR PROGNOSTIC BIOMARKERS OF EFFICACY AND SURVIVAL IN IPILIMUMAB-TREATED PATIENTS
    Publication number: 20150118244
    Abstract: Provided herein are prognostic and diagnostic methods and kits for use with the methods. For example, provided herein are methods for determining whether a subject having cancer will respond to a cancer treatment. For example, provided herein are methods for determining whether a subject having advanced melanoma will respond to a treatment with ipilimumab. Methods for determining the length of survival of cancer patients, e.g., melanoma patients, such as melanoma patients treated with ipilimumab, are also provided herein.
    Type: Application
    Filed: May 9, 2013
    Publication date: April 30, 2015
    Applicant: Bristol-Myers Squibb Company
    Inventors: Vafa Shahabi, Rui-Ru Ji
  • Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
    Patent number: 9017660
    Abstract: This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: April 28, 2015
    Assignees: Advaxis, Inc., The Trustees of the University of Pennsylvania
    Inventors: Vafa Shahabi, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew Seavey
  • METHODS FOR PREDICTING GASTROINTESTINAL IMMUNE-RELATED ADVERSE EVENTS (GI-IRAE) IN PATIENTS TREATED WITH MODULATION OF THE CO-STIMULATORY PATHWAY
    Publication number: 20150110779
    Abstract: The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a cancer patient will experience a gastrointestinal immune-related adverse event (GI-irAE) after administration of a pharmaceutically acceptable amount of an activator of the immune system.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 23, 2015
    Inventors: Vafa Shahabi, Ruiru Ji
  • Compositions and methods comprising KLK3 of FOLH1 antigen
    Patent number: 9012141
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: April 21, 2015
    Assignees: Advaxis, Inc., The Trustees of the University of Pennsylvania
    Inventors: Yvonne Paterson, John Rothman, Vafa Shahabi
  • DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS
    Publication number: 20140335120
    Abstract: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Inventors: Paulo MACIAG, Anu Wallecha, Vafa Shahabi
  • DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS
    Publication number: 20140314708
    Abstract: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 23, 2014
    Applicant: Advaxis, Inc.
    Inventors: Paulo Maciag, Anu Wallecha, Vafa Shahabi
  • COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
    Publication number: 20140234370
    Abstract: This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a human subject.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 21, 2014
    Applicant: Advaxis, Inc.
    Inventor: Vafa SHAHABI